Drug combination shows promise for newly diagnosed blood cancer patients, study finds

In early results, all participants responded to treatment with limited side effects

2010-12-10

(Press-News.org) ANN ARBOR, Mich. — A new three-drug combination used to treat the blood cancer multiple myeloma may be effective as a front-line therapy for newly diagnosed patients, according to a study led by the University of Michigan Comprehensive Cancer Center.

The drug combination includes a novel proteasome inhibitor called carfilzomib, combined with lenalidomide and low-dose dexamethasone. This is the first study to look at carfilzomib as a front-line treatment of patients with myeloma, a type of cancer that arises in the plasma cells.

Initial results of the phase I study were presented at the American Society of Hematology Annual Meeting and Exposition.

"This combination treatment appears to deliver everything we expected and more. We have seen no neurotoxicity and fantastic efficacy, the best reported to date," says study author Andrzej Jakubowiak, M.D., Ph.D., director of the multiple myeloma program at the University of Michigan Comprehensive Cancer Center.

The study, which still is accruing participants, has enrolled 31 people to date. All patients responded to this combination, measured by at least a 50 percent reduction of the disease, and the disease was completely or nearly eliminated in a significant portion of patients.

Responses were rapid, and the depth of response continued to improve with additional treatment. Of patients who completed eight cycles of therapy, more than two-thirds achieved a complete response, meaning they showed little or no signs of cancer. These response rates appear to be higher than those achieved by the best current regimens in newly diagnosed multiple myeloma.

After a median follow-up of six months, all patients were alive with no progression of their cancer.

Researchers found that the three-drug combination, called CRd, was well-tolerated, with few serious side effects. Most notably, peripheral neuropathy -- which is marked by numbness or tingling of the fingers and toes and can cause significant pain, depending on the severity -- was infrequent and mild with this treatment. This side effect typically limits extended use of currently available multiple myeloma treatments and is often the reason patients discontinue a therapy.

The study also included patients who were eligible for a stem cell transplant. The researchers found that these patients were able to remain on CRd treatment and achieved responses similar to or better than those observed after a stem cell transplant. This outcome delayed the need for a stem cell transplant in these patients.

"Newly diagnosed myeloma is most sensitive to treatment. A great response in the initial phase of treatment is critical because it projects how long patients will remain in remission, as well as their overall survival. Patients have a better chance of living longer if their response to initial treatment is better," says Jakubowiak, associate professor of internal medicine at the U-M Medical School.

Carfilzomib has recently emerged as an important drug in treatment of multiple myeloma. It has previously been tested as a single-agent in patients who have exhausted all available treatment options and in relapsed disease. Currently, a Phase III trial is ongoing looking at CRd compared with lenalidomide and low dose dexamethasone alone for patients with relapsed multiple myeloma.

Multiple myeloma statistics: 20,180 Americans will be diagnosed with multiple myeloma this year and 10,650 will die from the disease, according to the American Cancer Society

INFORMATION: Additional authors: Dominik Dytfeld, M.D., Ph.D., Tara B. Anderson, Brian Nordgren, Daniel Lebovic, M.D., Kent Griffith, Melissa Hill, Colleen Harvey, all from U-M; Sundar Jagannath, M.D., Mt. Sinai Medical Center; David H. Vesole, M.D., Ph.D., Hackensack University Medical Center; Keith Stockerl-Goldstein, M.D., and Ravi Vij, M.D., Washington University School of Medicine, St. Louis; Akari Dollard, Dana Farber Cancer Institute; Robert Ott and Susan L. Kelley, M.D., Multiple Myeloma Research Consortium; Jennifer Barrickman, Celgene Corp.; and Michael Kauffman, M.D., Onyx Pharmaceuticals Inc.

Funding: Multiple Myeloma Research Consortium, Onyx Pharmaceuticals Inc., Celgene Corporation and the U-M Comprehensive Cancer Center

Disclosure: none

Reference: 52nd American Society of Hematology Annual Meeting and Exposition, Dec. 4-7, 2010, Orlando, Fla.

Resources:
U-M Cancer AnswerLine, 800-865-1125
U-M Comprehensive Cancer Center, www.mcancer.org
Clinical trials at U-M, www.UMClinicalStudies.org

ELSE PRESS RELEASES FROM THIS DATE:

Chinese study suggests that alcohol increases angiographically significant coronary artery disease

2010-12-10

Among a large number of Chinese men presenting with chest pain or EKG changes, sequential subjects undergoing cardiac angiography were evaluated for obstructive coronary artery disease (CAD) lesions according to their reported recent alcohol intake. The study population consisted of 1,476 consecutive men 36 to 84 years of age; participants were categorized as nondrinkers, light drinkers, moderate drinkers, or heavy drinkers. Adjusted odds ratios for angiographically proved CAD for light, moderate, and heavy drinking were 1.16 (95% confidence interval 0.68 to 1.94), ...

A 'stitch in time' could help damaged hearts

2010-12-10

WORCESTER, Mass. – A research team at Worcester Polytechnic Institute (WPI) has demonstrated the feasibility of a novel technology that a surgeon could use to deliver stem cells to targeted areas of the body to repair diseased or damaged tissue, including cardiac muscle damaged by a heart attack. The technique involves bundling biopolymer microthreads into biological sutures and seeding the sutures with stem cells. The team has shown that the adult bone-marrow-derived stem cells will multiply while attached to the threads and retain their ability to differentiate and grow ...

IU study: When to end a run

2010-12-10

Runners who continue running when they are exhausted unknowingly change their running form, which could be related to an increased risk for injury. A study by Tracy Dierks, assistant professor of physical therapy at Indiana University, found that toward the end of a normal running session, runners generally displayed an increase in motion in their hips, knees and ankles. "Our study showed that at the end of a normal run, when they were getting tired, their mechanics were beginning to change," Dierks said. "When you notice fatigue, you're most likely putting yourself ...

Better batteries from the bottom up

2010-12-10

Rice University researchers have moved a step closer to creating robust, three-dimensional microbatteries that would charge faster and hold other advantages over conventional lithium-ion batteries. They could power new generations of remote sensors, display screens, smart cards, flexible electronics and biomedical devices. The batteries employ vertical arrays of nickel-tin nanowires perfectly encased in PMMA, a widely used polymer best known as Plexiglas. The Rice laboratory of Pulickel Ajayan found a way to reliably coat single nanowires with a smooth layer of a PMMA-based ...

Sesame Street program improves development for children in Indonesia

2010-12-10

Children exposed to Jalan Sesama, an Indonesian version of the children's television show Sesame Street, had improved educational skills and healthy development, according to a study by researchers at the Johns Hopkins Bloomberg School of Public Health. Over a 14-week period, the children who had the greatest exposure to Jalan Sesama improved significantly in literacy, mathematics, early cognitive skills, safety knowledge and social awareness, compared to those with no or low exposure to the program. The study is available online in advance of publication in the International ...

Cloud 'feedback' affects global climate and warming, says Texas A&M study

2010-12-10

COLLEGE STATION, Dec. 9, 2010 – Changes in clouds will amplify the warming of the planet due to human activities, according to a breakthrough study by a Texas A&M University researcher. Andrew Dessler, a professor in the Department of Atmospheric Sciences, says that warming due to increases in greenhouse gases will cause clouds to trap more heat, which will lead to additional warming. This process is known as the "cloud feedback" and is predicted to be responsible for a significant portion of the warming over the next century. Dessler used measurements from the Clouds ...

Stricter testing for federal ground beef program may not lead to safer meat

2010-12-10

WASHINGTON — A new National Research Council report finds no scientific basis that more stringent testing of meat purchased through the government's ground beef purchase program and distributed to various federal food and nutrition programs -- including the National School Lunch Program -- would lead to safer meat. The U.S. Department of Agriculture's Agricultural Marketing Service (AMS) buys ground beef from suppliers who must meet mandatory process, quality, traceback, and handling controls as well as comply with strict limitations on the amounts of bacteria in the ...

Simulations aim to unlock nature's process of biomineralization

2010-12-10

Columbus, Ohio – A University of Akron researcher is leveraging advanced modeling and simulation techniques to more precisely understand how organic materials bond to inorganic materials, a natural phenomenon that if harnessed, could lead to the design of composite materials and devices for such applications as bone replacement, sensing systems, efficient energy generation and treatment of diseases. Hendrik Heinz, Ph.D., an assistant professor of polymer engineering at UA, is accessing the systems of the Ohio Supercomputer Center (OSC) to study the process of biomineralization, ...

Pacific Biosciences and Harvard scientists decode genome of Haitian cholera pathogen

2010-12-10

Menlo Park, Calif. – December 9, 2010 – Scientists from Pacific Biosciences of California, Inc. (NASDAQ: PACB) and Harvard Medical School have successfully employed single molecule, real-time (SMRT™) DNA sequencing technology to rapidly characterize the pathogen responsible for the recent deadly cholera epidemic in Haiti. Published Thursday in the New England Journal of Medicine, the results provide the first whole genome sequence analysis and most detailed genetic profile to date of the Haitian Vibrio cholerae outbreak strain. The multi-strain sequencing and bioinformatic ...

Evolutionary arms race between smut fungi and maize plants

2010-12-10

Fungi are a major cause of plant diseases and are responsible for large-scale harvest failure in crops like maize and other cereals all over the world. Together with scientists from the Helmholtz Zentrum in Munich, Regine Kahmann, from the Max Planck Institute for Terrestrial Microbiology in Marburg, and Jan Schirawski, who is now based at the University of Göttingen, analysed the genetic make-up of Sporisorium reilianum, an important maize parasite. Based on a comparison with the genome of a related fungal species, they succeeded in identifying new genes that play an important ...

Several healthy diet patterns are associated with reduced risk of type 2 diabetes regardless of ethnicity – shows meta-analysis of more than 800,000 people

Liver fibrosis to cancer: scientists map path to block deadly transition

Microbiota boost immunotherapy? A meta-analysis dives into fecal microbiota transplantation and immune checkpoint inhibitors

Cancer's double agents: Fibroblasts both help and hinder immunotherapy

Unveiling large multimodal models in pulmonary CT: A comparative assessment of generative AI performance in lung cancer diagnostics

Indian adults who move to cities are significantly more likely to become obese than their rural counterparts - and the longer they stay, the greater the risk

[Press-News.org] Drug combination shows promise for newly diagnosed blood cancer patients, study finds
In early results, all participants responded to treatment with limited side effects

Drug combination shows promise for newly diagnosed blood cancer patients, study finds

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: